DEMOJUAN- DEMOnstration Area for Primary Prevention of Type 2 Diabetes, JUAN Mina and Barranquilla, Colombia

Type 2 Diabetes Clinical Trial

— DEMOJUAN  

Official title:

DEMOnstration Area for Primary Prevention of Type 2 Diabetes, JUAN Mina and Barranquilla, Colombia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01296100
• Other study ID #: LT09-258
• Status: Completed
• Phase: N/A
• First received: February 12, 2011
• Last updated: July 25, 2016
• Start date: February 2011
• Est. completion date: March 2015

Study information

• Verified date: July 2016
• Source: Centro de Investigacion Sanitaria
• Contact: n/a
• Is FDA regulated: No
• Health authority: Colombia: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The main aim of this study is to investigate to what extent it is possible to reach normal glucose metabolism and optimal cardiovascular disease (CVD) risk factor levels with early lifestyle interventions in people at high risk of type 2 diabetes compared with those who receive standard therapy (usual care) only.

The project will show the effect of these interventions for the first time in people of low socio-economic levels living in a Caribbean environment.

Description:

Type 2 diabetes (T2D) is one of the fastest growing public health problems in both developed and developing countries. The development of T2D is a slow process and involves both genetic and environmental effects. It is commonly agreed that T2D may develop only in people that carry a genetic predisposition to the disease. Based on epidemiological observations about half of the people will develop T2D during their lifetime, and up to 30-35% will have IGT. Therefore, it is likely that more than half of the population carry genes that predispose the development of T2D. In people genetically predisposed to the disease, the probability to develop T2D is very high once exposed to unhealthy lifestyles such as obesity, unbalanced diet and physical inactivity. While we cannot change the genes, the only way to prevent T2D and its serious complications is the modification of lifestyle risk factors. Therefore, it is very important to understand the role of preventive lifestyle intervention as a key treatment in T2D prevention. Once established, T2D is difficult to treat. Despite pharmacologic treatment blood glucose levels trend to increase over time. Thus, the most efficient way to manage T2D is to prevent diabetes from developing. Also complications of T2D can best be postponed by postponing the onset of the primary disease itself. The efforts to prevent the disease need to start as early as possible and address all susceptibility factors. Fortunately, recent studies have convincingly demonstrated that prevention of T2D is possible. This project will show for the first time how lifestyle interventions work in people with IGT in the Caribbean population. The results of this study will be sued for policy making and planning of primary prevention activities not only in the local health-care system but in the entire Caribbean region.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 730
• Est. completion date: March 2015
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 34 Years to 69 Years

Eligibility

Inclusion Criteria:

• 34-69 years-of-age with diagnosed IGT

• Informed consent given.

Exclusion Criteria:

• Patients with pharmacologically-treated diabetes

• Hypertriglyceridaemia under drug treatment

• History of life-limiting diseases or events

• Unwillingness to sign the informed consent.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Glucose Metabolism Disorders
• Metabolic Diseases
• Type 2 Diabetes

Intervention

Behavioral:
• Lifestyle intervention (nutrition)
The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
• Lifestyle intervention (physical activity)
The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.

Locations

Country	Name	City	State
Colombia	Camino Bosques de María	Barranquilla
Colombia	Camino Sur Occidente El Pueblo	Barranquilla
Colombia	Centro de INvestigacion Sanitaria	Barranquilla
Colombia	Paso Las Malvinas	Barranquilla
Colombia	Paso Nueva Era	Barranquilla

Sponsors (3)

Lead Sponsor	Collaborator
Centro de Investigacion Sanitaria	Helsinki University, International Diabetes Federation

Country where clinical trial is conducted

Colombia, 

References & Publications (3)

Lindström J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003 Dec;26(12):3230-6. — View Citation

Lindström J, Peltonen M, Eriksson JG, Aunola S, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study (DPS) Group. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care. 2008 May;31(5):857-62. doi: 10.2337/dc07-2162. Epub 2008 Feb 5. — View Citation

Schwarz PE, Li J, Lindstrom J, Tuomilehto J. Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res. 2009 Feb;41(2):86-97. doi: 10.1055/s-0028-1087203. Epub 2008 Nov 19. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of patients who reach normal levels of all glycaemic parameters.	Proportion of patients whose fasting glucose level is less than 6.1 mmol/l; Proportion of patients whose 2-hour glucose level is less than 7.8 mmol/l	Month 24 of the intervention	No
Secondary	Difference in reduction of 10 year-estimated cardiovascular risk score of 10% between the standard therapy control group and the lifestyle intervention groups (WHO CVD prediction chart).	Proportion of patients whose blood pressure level is less than 130/80 mmHg; Proportion of patients whose serum HDL cholesterol level is more than 1.2 mmol/l; Proportion of patients whose serum LDL cholesterol level is less than 2.0 mmol/l; Proportion of patients whose total/HDL cholesterol ratio is less than 4.0; Proportion of patients whose weight reduction is more than 5%	Month 24 of the intervention	No

External Links

•   Link